INOZYME PHARMA INC's ticker is INZY and the CUSIP is 45790W108. A total of 53 filers reported holding INOZYME PHARMA INC in Q3 2021. The put-call ratio across all filers is - and the average weighting 0.2%.
Links
Filings
- All filings
- Annual reports (10-K)
- Quarterly reports (10-Q)
- Insider transactions
- Shareholder votes
- Significant ownership
- Events
EDGAR links
External links
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $592,792 | -24.9% | 141,141 | -0.4% | 0.00% | – |
| Q2 2023 | $789,291 | +192.1% | 141,704 | +200.4% | 0.00% | – |
| Q1 2023 | $270,255 | +1171.5% | 47,165 | +133.0% | 0.00% | – |
| Q4 2022 | $21,255 | -60.6% | 20,243 | 0.0% | 0.00% | – |
| Q3 2022 | $54,000 | -48.6% | 20,243 | -7.6% | 0.00% | – |
| Q2 2022 | $105,000 | -36.0% | 21,898 | -45.3% | 0.00% | – |
| Q1 2022 | $164,000 | -41.6% | 40,013 | -2.9% | 0.00% | – |
| Q4 2021 | $281,000 | -40.1% | 41,196 | +1.9% | 0.00% | – |
| Q3 2021 | $469,000 | -24.7% | 40,418 | +10.6% | 0.00% | – |
| Q2 2021 | $623,000 | +34.8% | 36,546 | +56.6% | 0.00% | – |
| Q1 2021 | $462,000 | +5.0% | 23,337 | +9.3% | 0.00% | – |
| Q4 2020 | $440,000 | -13.6% | 21,349 | +10.1% | 0.00% | – |
| Q3 2020 | $509,000 | – | 19,385 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| CHI Advisors LLC | 1,009,117 | $26,529,000 | 9.44% |
| YALE UNIVERSITY | 113,502 | $2,984,000 | 9.13% |
| Sofinnova Investments, Inc. | 2,028,308 | $53,324,000 | 3.95% |
| Novo Holdings A/S | 2,569,379 | $67,549,000 | 3.35% |
| NEA Management Company, LLC | 2,444,379 | $64,263,000 | 2.72% |
| RA Capital Management | 2,003,653 | $52,676,000 | 0.96% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 1,150,299 | $30,241,000 | 0.74% |
| Rock Springs Capital Management LP | 879,954 | $23,134,000 | 0.59% |
| SPHERA FUNDS MANAGEMENT LTD. | 196,411 | $5,164,000 | 0.51% |
| Orbimed Advisors | 400,400 | $10,527,000 | 0.13% |